A meta-analysis showed that high Ki-67 expression is correlated with disease progression and poor outcome in lung cancer patients [81], although the assessment of Ki-67 expression using immunohistochemistry (IHC) is invasive and is often affected by tissue sample quality [82]. This evidence concerns the gene MKI67 and lung cancer.